Tokyo–(BUSINESS WIRE)–Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter “Elix”) and SEEDSUPPLY Inc. (CEO: Naoki Tarui / HQ: Kanagawa, hereinafter “SEEDSUPPLY”) hereby announce the start of joint research.
SEEDSUPPLY (https://www.seedsupply.co.jp/) proposes a flexible process for small molecule drug discovery that uses binder selection technology as a proprietary method for compound screening. This technology can perform integrated screening of any protein or RNA, thereby providing the seed for drug discovery of potential drug discovery targets, including those where measurement of biochemical activity is challenging. Additionally, a composite binding database developed for specific classes of drug discovery targets will be used for target selection, improving the efficiency and success rate of drug discovery processes. In addition, the database provides extensive functionality.
Elix (https://www.elix-inc.com/) is an AI drug discovery company with a mission to “rethink drug discovery.” In order to reduce costs and time while increasing the success rate of the drug discovery pipeline, Elix focuses on the use of machine learning in projects aimed at pharmaceutical companies, universities and research institutes. Elix developed and released “Elix Discovery™,” an All-in-one platform for AI drug discovery, which provides everything from predictive models and molecular design, to demonstration and implementation support in a single package (https:// www.elix-inc.com/news/newsrelease/1620/). In addition to currently providing drug discovery support, Elix is also considering domestic drug discovery in the future.
In this joint research project, SEEDSUPPLY will use Elix’s proprietary AI technology with the goal of dramatically increasing the efficiency of testing processes. Elix will integrate SEEDSUPPLY’s wealth of data, particularly its data on key drug discovery targets such as membrane proteins, into the AI training pipeline, thereby improving the technology in silicone techniques for testing compounds with high properties.
Elix and SEEDSUPPLY aim to leverage their respective strengths to reduce the cost and time of small molecule drug discovery and to address targets that have proven difficult in conventional drug discovery methods.
Elix CEO Shinya Yuki’s comments
By combining the data obtained through SEEDSUPPLY’s proprietary technology and our proprietary AI models, we hope to achieve even more unique technological advances. We believe that this technology will enable great opportunities for testing the most difficult targets at low cost within short times, as well as for efficiently searching extended chemical environments.
Comments from SEEDSUPPLY CEO Naoki Tarui
The binding integrated database of our company is of the highest quality, because all its content is measured using the same method. By combining it with Elix’s advanced AI technology, we hope to create a new breakthrough in AI drug discovery technology.